CURRICULUM VITAE

Alessandro Poggi, MSc, MD
Ministry of Health webpage: https://moh-it.pure.elsevier.com/en/persons/alessandro-poggi
ORCID: https://orcid.org/0000-0002-1860-430X
Scopus ID 7101947825 https://www.scopus.com/authid/detail.uri?authorId=7101947825
Scopus Index: **56**, **11024 citations**
Loop website: https://loop.frontiersin.org/people/29615/overview
Research gate website: https://www.researchgate.net/profile/Alessandro_Poggi
Linkedin website: https://www.linkedin.com/in/alessandro-poggi-472981aa/
Laboratory website: https://www.ospedalesanmartino.it/ospedale/dipartimenti/in-line-direttore-scientifico/item/388-oncologia-molecolare-e-angiogenesi.html

Personal Data:

Place and Date of Birth: Genoa, 28th September 1959.
Marital Status: Married.
Address: Via Eleonora Duse 74/3, I-1646 Genoa.
e-mail: alessandropoggi1959@gmail.com sandropoggi59@hotmail.it

Education:

1982: Degree in Biology, University of Genoa, Italy (110/110 cum laude).
1983: Qualification as a Biologist (150/150).
1983-1987: Postdoctoral Degree in General Pathology, University of Genoa (70/70 cum laude).
1993-2000: Medical Doctor and Surgery degree, University of Genoa, Italy (110/110 cum laude).
2001: Qualification as a Medical Doctor (94/100).
2004: Postdoctoral Degree in Allergology and Clinical Immunology, University of Genoa (50/50 cum laude).
2013: Scientific Abilitation as full professor in Molecular Oncology
2013: Scientific Abilitation as full professor in Pathology

Scientific Career:

1980-1982: Attendance to the Departments of Microbiology and Chemistry, University of Genoa.
1982-1985: Attendance to the Department of Internal Medicine, Laboratory of Clinical Immunology, University of Genoa, Italy.
1985-1987: Post-Doctoral Fellow at the Human Immunology Laboratory, Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland.
1987-1996: Assistant Member, Laboratory of Immunopathology, National Institute for Cancer Research, Genoa, Italy.
1993: Deputy Director, Biotechnology Department, National Institute for Cancer Research, Rome.
2000-2008: Attendance as a Physician to the Department of Internal Medicine, University of Genoa.
1997-2009: Deputy Director, Laboratory of Immunopathology (now: Laboratory of Immunology), National Institute for Cancer Research, Genoa.
July 2009-today, Head of the Molecular Oncology and Angiogenesis Unit, IRCCS AOU San Martino IST-National Institute for Cancer Research, (now IRCCS Ospedale Policlinico San Martino), Genoa.
1st October 2024.: retired from Head of the Molecular Oncology and Angiogenesis Unit, IRCCS AOU San Martino IST-National Institute for Cancer Research, (now IRCCS Ospedale Policlinico San Martino), Genoa.

Teaching Appointments University of Genoa

2014-2023: 10h/year (AA14-15, 15-16, 16-17, 17-18, 18-19, 19-20, 20.21, 21-22, 22-23); Professor of Clinical Pathology III, Biomedical Techinician course at University of Genoa, total 90h.
2015-2023: 10h/year (AA15-16, 16-17, 17-18, 18-19, 19-20, 20.21, 21-22, 22-23); Professor of Clinical Pathology I, Biomedical Techinician course at University of Genoa, total 80h.
2020-2023: 8h/year (AA 20-21, 21-22, 22-23) General Pathology and Pharmacology for TSRM course at University of Genoa, total 24h
2019-2023 16h/year (AA 19-20, 20-21, 21-22, 22-23) Professor of Molecular Oncology and Immunology, at the course of Medical Pharmaceutical Biotechnology, University of Genoa, total 64.
2024-2025 Professor of Molecular Oncology and Immunology, at the course of Medical Pharmaceutical Biotechnology, University of Genoa, 16h.

Other Teaching Appointments
September 1989: Teacher at the Practical Course: "Immunodiagnosis and Immunotherapy of Cancer", School of Oncology and Biomedical Sciences, Genoa.
November 1989: Teacher at the Practical Course: "Manipulation of immunocompetent cells in oncology", School of Oncology and Biomedical Sciences, Genoa.
April 1991 and April 1992: Teacher at the Practical Course: "Tecniques of cell culture in immunology", School of Oncology and Biomedical Sciences, Genoa.
November 1993: Teacher at the Practical Course: "Expert in Biotechnology", School of Oncology and Biomedical Sciences, Genoa.
1991-1993: Teacher of Immunology at the Faculty of Medicine, University of Turin, Italy.
1990-today: Tutorial for Doctoral and Post Doctoral Students, Faculty of Medicine, Faculty of Biology, School of Biotechnology, Post Doctoral School of Oncology and Post Doctoral School of Clinical Pathology.

Editorial Board Member
2008: Curr. Med. Chem. – Anti-Inflammatory & Anti-Allergy Agents.
2008: The Open Autoimmunity Journal.
2012: Lymphoma and Chronic lymphocytic leukemia
2012. World journal of Immunology
2012: World Journal of Hematology
2018: Cells (MDPI) (ISSN 2073-4409)
2018: International Journal of Molecular Sciences (MDPI)
2018: Clinical Journal of Oncology and Cancer Research (Vivid Ed.)

Reviewer of the following research journal
1992: Journal of Immunology
1993: International Immunology
1994: Experimental Cell Research
1996: European Journal of immunology
1999: International Journal of Cancer
2000: Journal of Cellular Biochemistry
2002: Blood
2002: Trends in Immunology
2003: Journal of Infectious Disease
2006: Cancer Research
2006: Immunology Letters
2007: Experimental Hematology
2007: BioTecqniques
2007: Critical Reviews in Immunology
2008: Human Immunology
2008: Stem cells and Development
2008: European Journal of Cancer
2008: Leukemia
2008: Cancer Immunology Immunotherapy
2008: FEBS Letter
2009: Immunotherapy
2009: Cancer Research Therapy
2009: Apoptosis
2009: Journal of Global Infectious Disease
2009: Journal of Histochemistry and Cytochemistry

2009: Journal of Clinical Immunology
2010: Immunology
2010: Haematologica/Hematology Journal
2011: Molecules
2011: Disease Markers
2011: OncoImmunology
2011: Hematological Oncology
2011: World Journal of Gastroenterology
2011: World Journal of Hematology
2011: Molecular Immunology
2011: Medicinal Chemistry
2012: Journal of Leukocyte Biology
2012: International Journal of Immunopathology and Pharmacology
2012: Frontiers in Immunology
2012: Indian Journal of Medical Research
2012: Journal of Cell Death
2012: Cell proliferation
2012: Current Immunology Reviews
2013: PlosOne
2013: Clinical and Experimental Medicine
2013: Tokuku Journal of Experimental medicine
2013: Cellular an Molecular Life Sciences
2013: Clinical and Experimental Immunology
2014: Genes and Immunity
2014: Cellular and Molecular Immunology
2014: BioMed Research International
2014: Cell Biochemistry and Biophysics
2014: BMC Immunology
2014: Cell Comunication and Signalling
2014: Cellular Physiology and Biochemistry
2014: Clinical Cancer Drug
2015: Artificial Cells, Nanomedicine and Biotechnology
2015: Journal of Cytology and Pathology
2016: Critical Reviews™ in Immunology
2016: Cancer microenvironment
2016: Frontiers in Pharmacology
2017: APMIS
2017: Current Opinion in Pharmacology
2017: European Journal Pharmacology
2017: Future in Oncology
2017: Histochemistry and Cell biology
2017: Journal of Drug Design and Research
2017: Translational Oncology
2017: Tumor and microenvironment
2017: Journal of Emerging Disease and Virology
2017: Frontiers in Oncology
2018: Frontiers Pediatrics
2020: Blood Advances
2020: Translational Cancer Research
2020: Cancer Letters

Memberships:

1987-1999: Gruppo di Cooperazione in Immunologia.
1999-2001: Società Italiana di Immunologia (ex Gruppo di Cooperazione in Immunologia)
1989-2003: Gruppo Italiano di Citometria
1990-today: European Association for Cancer Research
1990-today: Società Italiana di Ematologia Sperimentale
1991-1999: Società Italiana di Biochimica
2001-today: Società Italiana di Immunologia Clinica e Allergologia
2002-2004: American Association of Immunologists
2004-today: European Association of Hematology

Research Funding:
1990-1997: Contributes to grants funded by the Italian Association for Cancer Research (AIRC), the Italian Institute of Health-AIDS Program and the Italian National Institute of Health.
1997-2000: Co-investigator for a research program funded by AIRC.
1998-2000: Principal Investigator for the research project "Regulation of cytokine secretion in dendritic cells and natural killer cells", funded by Italian Institute of Health (Coordinated by A.Rubartelli, Protein Biology Unit, National Institute for Cancer Research, Genoa).
2000-2002: Principal Investigator for the research project "Inhibition of leucocyte migration in multiple sclerosis: a new approach bases on troian peptides", funded by the Italian Institute of Health (Coordinated by L.Battistini, Neuroimmunology Unit, Scientific Institute S.Lucia, Rome).
2000-2002: Principal Investigator for the research project "Soluble factors in tumor microenvironment: induction of chemotaxis and anticancer immunity", funded by Italian Institute of Health (Coordinated by A.Rubartelli, Protein Biology Unit, National Institute for Cancer Research).
2002-2004: Principal Investigator for the research project "Molecular analysis and regulation of tumor target cell-induced apoptosis of cytotoxic effector cells", funded by AIRC.
2002-2004: Principal Investigator for the research project "Enhancement of the anti-tumor immune response in lymphoproliferative disorders", funded by the Italian National Institute of Health (Coordinated by M.Ferrarini, National Institute for Cancer Research, Genoa, Italy)
2002-2004: Principal Investigator for the research project "Study of new effector lymphocyte populations in multiple sclerosis" (Coordinator L. Battistini, Neuroimmunology Unit, S.Lucia Foundation, Rome, Italy)
2005-2008. Principal Investigator for the research project "Molecular analysis and regulation of leukemic cell-induced apoptosis of cytotoxic effector cells." funded by the Italian Association for Cancer Research (AIRC) (110.000 euros).
2007-2009. Principal Investigator for the research project: "Role of tumour stromal cells and soluble factors in lymphoma-mediated immune suppression." Funded by Compagnia del San Paolo, Italy (249.000 euros).
2009-2011. Principal Investigator of the research project: "Role of tumour stromal cells and soluble factors in lymphoma-mediated immune suppression", funded by the Italian Association for Cancer Research (AIRC) (150.000 euros).
2011-2012. Principal Investigator of the research project: "Lymph-node stromal cells as target cells for lymphoma therapy", funded by Compagnia del San Paolo, Italy (140.000 euros).
2012-2014. Co-investigator of the research project. "Drug targeting to control colorectal and prostate cancer: effects on cancer cells, stromal cells and immune system.", funded by Compagnia del San Paolo (46.550 euros).
2014-2016. Principal Investigator of the research project: ""Mesenchymal stromal cell regulation of NKG2D- and cetuximab-mediated anti-tumor immune response in colorectal carcinoma", funded by AIRC IG15483 (262.000 euros).
2019-2024. Principal Investigator of the research project: "γδT and natural killer cell immune response in colorectal cancer: double targeting with zoledronic acid and cetuximab"," funded by AIRC IG21648 (644,000 euros).

2020-2022: Principal Investigator of the research project: "Patient-specific organoid to measure the immune response elicited by zoledronate/anti-EGFR antibody conjugate in colon cancer", funded by Compagnia del San Paolo (155.300 euros)

Publication (in bold the Impact Factor according to ISI 2011, NI not indexed)

1. Viglione D, Pierri I, Rogna S, Barabino A, Franceschini R, Poggi A, Indiveri F. T lymphocytes in ageing humans: phenotypic and functional analysis. IRCS Med. Sci.1983; 11:1070-1071.
NI

2. Indiveri F, Pierri I, Rogna S, Poggi A, Montaldo P, Romano R, Pende A, Morgano A, Barabino A, Ferrone S. Circadian variations of autologous mixed lymphocyte reactions and endogenous cortisol. J Immunol Methods 1985 Sep 3;82(1):17-24
2.347

3. Mingari MC, Gerosa F, Maggi E, Cozzani R, Pende D, Bottino C, Poggi A, Romagnani S, Moretta L. Heterogeneity of B cell growth factor (BCGF)-producing T cells in humans. Clonal analysis of BCGF-producing cells within T4+ and T8+ subsets and evidence for the involvement of different growth factors in different BCGF assays. Ric Clin Lab 1986 Jan-Mar;16(1):23-8
1.063

4. Indiveri F, Pierri I, Rogna S, Poggi A, Romano R, Tavano A, Ratto G, Motta G, Ferrone S. Abnormalities of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma: deficit in PHA-induced expression of HLA class II antigens and in autologous mixed lymphocyte reactions. Cancer Immunol Immun 1986;22(3):232-5
3.791

5. Pende D, Poggi A, Scudeletti M, Criscuolo D, Indiveri F. The effects of a new phthalazine derivative (MDL 899) on human lymphocyte functions. Int J Immunopharmacol 1986;8(4):385-90
2.214

6. Mingari MC, Pende D, Cozzani R, Merli A, Poggi A, Ferrini S, Moretta L. Both the precursors and the effectors of human lymphokine-activated killer (LAK) cells may belong to T lymphocytes. Ric Clin Lab 1986 Jul-Sep;16(3):437-41
1.063

7. Moretta A, Olive D, Poggi A, Pantaleo G, Mawas C, Moretta L. Modulation of surface T11 molecules induced by monoclonal antibodies: analysis of the functional relationship between antigen-dependent and antigen-independent pathways of human T cell activation. Eur J Immunol 1986 Nov;16(11):1427-32
5.179

8. Pantaleo G, Olive D, Harris D, Poggi A, Moretta L, Moretta A. Signal transducing mechanisms involved in human T cell activation via surface T44 molecules. Comparison with signals transduced via the T cell receptor complex. Eur J Immunol 1986 Dec;16(12):1639-42
5.179

9. Pantaleo G, Olive D, Poggi A, Kozumbo WJ, Moretta L, Moretta A. Transmembrane signalling via the T11-dependent pathway of human T cell activation. Evidence for the involvement of 1,2-diacylglycerol and inositol phosphates. Eur J Immunol 1987 Jan;17(1):55-60
5.179

10. Moretta A, Poggi A, Olive D, Bottino C, Fortis C, Pantaleo G, Moretta L. Selection and characterization of T-cell variants lacking molecules involved in T-cell activation (T3 T-cell receptor, T44, and T11): analysis of the functional relationship among different pathways of activation. Proc Natl Acad Sci U S A 1987 Mar;84(6):1654-8
9.432

11. Poggi A, Bottino C, Zocchi MR, Pantaleo G, Ciccone E, Mingari C, Moretta L, Moretta A. CD3+ WT31- peripheral T lymphocytes lack T44 (CD28), a surface molecule involved in activation of T cells bearing the alpha/beta heterodimer. Eur J Immunol 1987 Jul;17(7):1065-8
5.179

12. Pantaleo G, Ol.ive D, Zocchi MR, Poggi A, Bottino C, Moretta A. Signal transducing mechanisms in human T cell activation . In : Genotypic and Functional Aspects of Haematopoiesis. (F. Grignani, M.F. Martelli and D.Y. Mason Eds) Raven Press 1987; 41:197-204.
NI

13. Bottino C, Poggi A, Zocchi MR, Pantaleo G, Moretta A. Analysis of the pathway of human T cell activation. In : Genotypic and Functional Aspects of Haematopoiesis. (F. Grignani, M.F. Martelli and D.Y. Mason Eds) Raven Press 1987; 41:173-179.
NI

14. Ferrini S, Bottino C, Biassoni R, Poggi A, Sekaly RP, Moretta L, Moretta A. Characterization of CD3+, CD4-, CD8- clones expressing the putative T cell receptor gamma gene product. Analysis of the activation pathways leading to interleukin 2 production and triggering of the lytic machinery. J Exp Med 1987 Jul 1;166(1):277-82
14.505

15. Pantaleo G, Olive D, Poggi A, Pozzan T, Moretta L, Moretta A. Antibody-induced modulation of the CD3/T cell receptor complex causes T cell refractoriness by inhibiting the early metabolic steps involved in T cell activation. J Exp Med 1987 Aug 1;166(2):619-24
14.505

16. Pantaleo G, Zocchi MR, Ferrini S, Poggi A, Tambussi G, Bottino C, Moretta L, Moretta A. Human cytolytic cell clones lacking surface expression of T cell receptor alpha/beta or gamma/delta. Evidence that surface structures other than CD3 or CD2 molecules are required for signal transduction. J Exp Med 1988 Jul 1;168(1):13-24.
14.505

17. Poggi A, Zocchi MR. Activation and proliferation of human T and B lymphocytes through a novel surface structure defined by the monoclonal antibody CK226: In: Leukocyte Typing IV. (W. Knapp Ed.), Oxorford University Press, 1989; 375-376.
NI

18. Zocchi MR, Poggi A. LAK1 and LAK2 monoclonal antibodies identified two different molecules expressed on large granular lymphocytes and lymphokine activated killer cells. In: Leukocyte Typing IV. (W. Knapp Ed.), Oxorford University Press, 1989; 727-728.
NI

19. Poggi A, Zocchi MR, Moretta L, Moretta A. CK226: a novel surface molecule involved in human T cell activation. Eur J Immunol 1989 Nov;19(11):2069-74
5.179

20. Zocchi MR, Heltai S, Poggi A. Dual-parameter flow cytometric analysis of an early lymphocyte activation antigen (CK226) and DNA content. Cytometry 1989 Nov;10(6):762-71
3.032

21. Zocchi MR, Poggi A, Mariani S, Gianazza E, Rugarli C. Identification of a new surface molecule expressed by human LGL and LAK cells production of a specific monoclonal antibody and comparison with other NK/LAK markers. Cell Immunol 1989 Nov;124(1):144-57.
2.698

22. Zocchi MR, Marelli F, Poggi A. Simultaneous cytofluorometric analysis for the expression of cytoplasmic antigens and DNA content in CD3- human thymocytes. Cytometry 1990;11(8):883-7
3.032

23. Heltai S, Poggi A, Sabbadini MG, Zocchi MR. Evaluation of cytotoxic cell-target cell conjugates. Comparison between flow cytometric analysis and 51Cr binding assay. Haematologica 1990 Mar-Apr;75(2):191-3
6.416

24. Poggi A, Maggi E, Biagiotti R, Giudizi MG, Almerigogna F, Pella N, Caligaris-Cappio F, Romagnani S, Moretta L. A novel pathway of human B cell activation initiated by CK226 surface antigen. Eur J Immunol 1990 May;20(5):1161-5
5.179

25. De Maria AF, Malnati MS, Poggi A, Pende D, Cottafava F, Moretta L. Clonal analysis of joint fluid T lymphocytes in patients with juvenile rheumatoid arthritis. J Rheumatol 1990 Aug;17(8):1073-8
3.854
26. Zocchi MR, Marelli F, Poggi A. CD1+ thymocytes proliferate and give rise to functional cells after stimulation with monoclonal antibodies recognizing CD3, CD2 or CD28 surface molecules. Cell Immunol 1990 Sep;129(2):394-403
2.698
27. Zocchi MR, Poggi A, Heltai S, Villa A, Inverardi L, Vicari A, Sabbadini MG, Ferrarini M. Signal requirements for activation of leukaemic T cells from a chronic lymphocytic leukaemia (T-CLL). Clin Exp Immunol 1990 Oct;82(1):108-13
3.009
28. Ferrarini M, Ferrero E, Fortis C, Poggi A, Zocchi MR. LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes. Br J Cancer 1990 Nov;62(5):754-7
4.346
29. Poggi A, Biassoni R, Pella N, Paolieri F, Bellomo R, Bertolini A, Moretta L, Mingari MC. In vitro expansion of CD3/TCR- human thymocyte populations that selectively lack CD3 delta gene expression: a phenotypic and functional analysis. J Exp Med 1990 Nov 1;172(5):1409-18
14.505
30. Mingari MC, Poggi A, Bellomo R, Pella N, Moretta L. Thymic origin of some natural killer cells: clonal proliferation of human CD3-16+ cells from CD3-4-8- thymocyte precursors requires the presence of H9 leukemic cells. Int J Clin Lab Res 1991;21(2):176-8
1.063
31. Mingari MC, Poggi A, Biassoni R, Bellomo R, Ciccone E, Pella N, Morelli L, Verdiani S, Moretta A, Moretta L. In vitro proliferation and cloning of CD3- CD16+ cells from human thymocyte precursors. J Exp Med 1991 Jul 1;174(1):21-6
14.505
32. Zocchi MR, Fabbri M, Poggi A, Gianazza E. Biochemical characterization by two-dimensional electrophoresis of lymphocyte antigens involved in cell-to-cell or cell-to-matrix adhesion. Electrophoresis 1991 Jul-Aug;12(7-8):527-35
3.077
33. Zocchi MR, Poggi A. Activation of CD3/TCR negative human thymocytes via CD28 molecule. Cell Immunol 1991 Aug;136(1):105-12
2.698
34. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, Pella N, Augugliaro R, Bottino C, Ciccone E, Moretta L. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta. J Exp Med 1991 Dec 1;174(6):1393-8
14.505
35. Vidal MJ, Zocchi MR, Poggi A, Pellegatta F, Chierchia SL. Involvement of nitric oxide in tumor cell adhesion to cytokine-activated endothelial cells. J Cardiovasc Pharmacol 1992;20 Suppl 12:S155-9
2.826
36. Zocchi MR, Poggi A, Crosti F, Tongiani S, Rugarli C. Signalling in human tumour infiltrating lymphocytes: the CD28 molecule is functional and is physically associated with the CD45R0 molecule. Eur J Cancer 1992;28A(4-5):749-54
4.454
37. Poggi A, Zocchi MR. Antigen-independent pathways of T-cell activation are functional in human immature thymocytes. Int J Clin Lab Res 1992;21(4):304-9
1.063
38. Zocchi MR, Poggi A. NCAM is involved in the adhesion of human LFA1 negative thymic and peripheral lymphocytes to endothelial cells. In: Recent Advances In Cellular And Molecular Biology, (Wegmann RJ, and Wegmann MA Eds) Peeters Press, 1992; Vol.1, 121-127.
NI

39. Poggi A. The leukocyte common antigen regulates the [Ca++]I increase mediated via the lymphocyte function associated antigen-1 in CD3-CD16+ peripheral lymphocytes. In: Recent Advances In Cellular And Molecular Biology, (Wegmann RJ, and Wegmann MA Eds) Peeters Press, 1992; 63-69.
NI

40. Poggi A, Zocchi MR. Cultured human thymocytes lacking CD2 and CD11a/CD18 antigens are functional and adhere to endothelial cells via CD56 or CDw49d molecules. Cell Immunol 1992 Apr;140(2):319-30
2.698

41. Zocchi MR, Vidal M, Poggi A. Involvement of CD56/N-CAM molecule in the adhesion of human solid tumor cell lines to endothelial cells. Exp Cell Res 1993 Jan;204(1):130-5
3.589

42. Zocchi MR, Poggi A, Crosti F, Tongiani S, Rugarli C. Signal transduction in human tumor infiltrating lymphocytes. Arch Immunol Ther Exp (Warsz) 1993;41(1):33-9
1.689

43. Tripodi G, Poggi A, Orengo AM, Pella N, Vitale M, Sivori S, Bottino C, Morelli L, Barbaresi M, Revello V, et al. Identification of a new surface molecule involved in the mechanism of cell to cell adhesion between human NK and tumor target cells. Cytotechnology 1993;11 Suppl 1:S109-11
0.977

44. Zocchi MR, Poggi A. NCAM and lymphocyte adhesion in leucocyte adhesion deficiency (LAD) syndrome. Immunol Today 1993 Feb;14(2):94-5
9.480

45. Zocchi MR, Poggi A. Lymphocyte-endothelial cell adhesion molecules at the primary tumor site in human lung and renal cell carcinomas. J Natl Cancer Inst 1993 Feb 3;85(3):246-7
14.069

46. Poggi A, Sargiacomo M, Biassoni R, Pella N, Sivori S, Revello V, Costa P, Valtieri M, Russo G, Mingari MC, et al. Extrathymic differentiation of T lymphocytes and natural killer cells from human embryonic liver precursors. Proc Natl Acad Sci U S A 1993 May 15;90(10):4465-9
9.432

47. Poggi A, Pardi R, Pella N, Morelli L, Sivori S, Vitale M, Revello V, Moretta A, Moretta L. CD45-mediated regulation of LFA1 function in human natural killer cells. Anti-CD45 monoclonal antibodies inhibit the calcium mobilization induced via LFA1 molecules. Eur J Immunol 1993 Oct;23(10):2454-63
5.179

48. Moretta L, Ciccone E, Poggi A, Mingari MC, Moretta A. Origin and functions of human natural killer cells. Int J Clin Lab Res 1994;24(4):181-6
1.063

49. Ferrini S, Sforzini S, Cambiaggi A, Poggi A, Meazza R, Canevari S, Colnaghi MI, Moretta L. The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes. Int J Cancer 1994 Mar 15;56(6):846-52
4.722

50. Cantoni C, Cambiaggi A, Sforzini S, Poggi A, Viale M, Biassoni R, Ferrini S. Characterization of a cyclosporin A-sensitive activation pathway in cultured T and natural killer cells. Scand J Immunol 1994 Apr;39(4):373-9
2.108

51. Moretta L, Ciccone E, Poggi A, Mingari MC, Moretta A. Ontogeny, specific functions and receptors of human natural killer cells. Immunol Lett 1994 May;40(2):83-8
2.906

52. Poggi A, Demarest JF, Costa P, Biassoni R, Pella N, Pantaleo G, Mingari MC, Moretta L. Expression of a wide T cell receptor V beta repertoire in human T lymphocytes derived in vitro from embryonic liver cell precursors. Eur J Immunol 1994 Sep;24(9):2258-61
5.179

53. Zocchi MR, Ferrero E, Toninelli E, Castellani P, Poggi A, Rugarli C. Expression of N-CAM by human renal cell carcinomas correlates with growth rate and adhesive properties. Exp Cell Res 1994 Oct;214(2):499-509

3.589

54. Poggi A, Pella N, Sivori S, Morelli L, Revello V, Vitale M, Moretta L, Moretta A. A novel p40 molecule involved in the regulation of NK-cell-mediated cytolytic activity. Leukocyte Typing V 1995;

NI

55. Poggi A, Pella N, Morelli L, Spada F, Revello V, Sivori S, Augugliaro R, Moretta L, Moretta A. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans. Eur J Immunol 1995 Feb;25(2):369-76

5.179

56. Mingari MC, Vitale C, Cambiaggi A, Schiavetti F, Melioli G, Ferrini S, Poggi A. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int Immunol 1995 Apr;7(4):697-703

3.403

57. Poggi A, Mingari MC. Development of human NK cells from the immature cell precursors. Semin Immunol 1995 Apr;7(2):61-6

9.155

58. Zocchi MR, Poggi A. Human gamma delta T lymphocytes use N-CAM to interact with the subendothelial matrix. J Natl Cancer Inst 1995 Jun 7;87(11):846-7

15.687

59. Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M, Conte R, Poggi A, Moretta A, Moretta L. The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996 Feb 1;183(2):645-50

14.505

60. Mingari MC, Cambiaggi A, Vitale C, Schiavetti F, Bellomo R, Poggi A. Effect of superantigens on human thymocytes: selective proliferation of V beta 2+ cells in response to toxic shock syndrome toxin-1 and their deletion upon secondary stimulation. Int Immunol 1996 Feb;8(2):203-9

3.403

61. Han D, Pottin-Clemenceau C, Imro MA, Scudeletti M, Doucet C, Puppo F, Brouty-Boye D, Vedrenne J, Sahraoui Y, Brailly H, Poggi A, Jasmin C, Azzarone B, Indiveri F. IL2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL2/INFalpha biotherapy. Oncogene 1996 Mar 7;12(5):1015-23

7.535

62. Poggi A, Panzeri MC, Moretta L, Zocchi MR. CD31-triggered rearrangement of the actin cytoskeleton in human natural killer cells. Eur J Immunol 1996 Apr;26(4):817-24

5.179

63. Poggi A, Spada F, Costa P, Tomasello E, Revello V, Pella N, Zocchi MR, Moretta L. Dissection of lymphocyte function-associated antigen 1-dependent adhesion and signal transduction in human natural killer cells shown by the use of cholera or pertussis toxin. Eur J Immunol 1996 May;26(5):967-75

5.179

64. Poggi A, Costa P, Morelli L, Cantoni C, Pella N, Spada F, Biassoni R, Nanni L, Revello V, Tomasello E, Mingari MC, Moretta A, Moretta L. Expression of human NKRP1A by CD34+ immature thymocytes: NKRP1A-mediated regulation of proliferation and cytolytic activity. Eur J Immunol 1996 Jun;26(6):1266-72

5.179

65. Poggi A, Pella N, Cantoni C, Zocchi MR, Moretta L. Physical and functional association of CD45 and CD3-TCR complex on CD1+ human thymocytes. Evidence that the engagement of CD45 molecules can prevent CD1+ thymocytes from apoptosis. Int Immunol 1996 Dec;8(12):1947-53

3.403

66. Moretta A, Biassoni R, Bottino C, Pende D, Vitale M, Poggi A, Mingari MC, Moretta L. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997 Feb;155:105-17

10.050

67. Poggi A, Tomasello E, Costa P. NKRP1A and p40 molecules are involved in regulation of activation and maturation of human NK cells. Res Immunol 1997 Mar-Apr;148(3):179-84
NI
68. Poggi A, Costa P, Zocchi MR, Moretta L. NKRP1A molecule is involved in transendothelial migration of CD4+ human T lymphocytes. Immunol Lett 1997 Jun 1;57(1-3):121-3
2.906
69. Davodeau F, Peyrat MA, Necker A, Dominici R, Blanchard F, Leget C, Gaschet J, Costa P, Jacques Y, Godard A, Vie H, Poggi A, Romagne F, Bonneville M. Close phenotypic and functional similarities between human and murine alphabeta T cells expressing invariant TCR alpha-chains. J Immunol 1997 Jun 15;158(12):5603-11
5.646
70. Zocchi MR, Poggi A, Rubartelli A. The RGD-containing domain of exogenous HIV-1 Tat inhibits the engulfment of apoptotic bodies by dendritic cells. AIDS 1997 Aug;11(10):1227-35
4.909
71. Rubartelli A, Poggi A, Zocchi MR. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium. Eur J Immunol 1997 Aug;27(8):1893-900
5.179
72. Poggi A, Tomasello E, Revello V, Nanni L, Costa P, Moretta L. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes. Int Immunol 1997 Sep;9(9):1271-9
3.403
73. Poggi A, Costa P, Zocchi MR, Moretta L. Phenotypic and functional analysis of CD4+ NKRP1A+ human T lymphocytes. Direct evidence that the NKRP1A molecule is involved in transendothelial migration. Eur J Immunol 1997 Sep;27(9):2345-50
5.179
74. Poggi A, Rubartelli A, Moretta L, Zocchi MR. Expression and function of NKRP1A molecule on human monocytes and dendritic cells. Eur J Immunol 1997 Nov;27(11):2965-70
5.179
75. Moretta L, Poggi A, Nanni L, Bottino C, Melioli G, Biassoni R, Moretta A. Natural Killer cell antigens: Section Report, In: Leukocyte Typing VI, (Kishimoto T et al. Eds), 1997; 265-267.
NI
76. Nanni L, Poggi A. CD3z Workshop Panel Report, In: Leukocyte Typing VI, (Kishimoto T et al. Eds), 1997; 268-269.
NI
77. Tomasello E, Revello V, Poggi A. CD16 Workshop Panel Report, In: Leukocyte Typing VI, (Kishimoto T et al. Eds), 1997; 269-271.
NI
78. Poggi A, Revello V, Nanni L, Costa P, Moretta L. CD161 (human NKR-P1A) Workshop Panel Report, In: Leukocyte Typing VI, (Kishimoto T et al. Eds), 1997; 307-312.
NI
79. Poggi A Costa P. Unclustered Natural Killer cell antigen Workshop Panel Report, In: Leukocyte Typing VI, (Kishimoto T et al. Eds), 1997; 317-318.
NI
80. Ferrero E, Bondanza A, Leone BE, Manici S, Poggi A, Zocchi MR. CD14+ CD34+ peripheral blood mononuclear cells migrate across endothelium and give rise to immunostimulatory dendritic cells. J Immunol 1998 Mar 15;160(6):2675-83
5.646
81. Poggi A, Rubartelli A, Zocchi MR. Involvement of dihydropyridine-sensitive calcium channels in human dendritic cell function. Competition by HIV-1 Tat. J Biol Chem 1998 Mar 27;273(13):7205-9
5.328

82. Poggi A, Costa P, Tomasello E, Moretta L. IL-12-induced up-regulation of NKRP1A expression in human NK cells and consequent NKRP1A-mediated down-regulation of NK cell activation. Eur J Immunol 1998 May;28(5):1611-6
5.179
83. Poggi A, Tomasello E, Ferrero E, Zocchi MR, Moretta L. p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. Eur J Immunol 1998 Jul;28(7):2086-91
5.179
84. Ferrero E, Fabbri M, Poggi A, Galati G, Bernasconi S, Zocchi MR. Tumor-driven matrix invasion by infiltrating lymphocytes: involvement of the alpha1 integrin I-domain. Eur J Immunol 1998 Aug;28(8):2530-6
5.179
85. Zocchi MR, Rubartelli A, Morgavi P, Poggi A. HIV-1 Tat inhibits human natural killer cell function by blocking L-type calcium channels. J Immunol 1998 Sep 15;161(6):2938-43
5.646
86. Rubartelli A, Poggi A, Sitia R, Zocchi MR. HIV-I Tat: a polypeptide for all seasons. Immunol Today 1998 Dec;19(12):543-5
9.480
87. Poggi A, Zocchi MR, Costa P, Ferrero E, Borsellino G, Placido R, Galgani S, Salvetti M, Gasperini C, Ristori G, Brosnan CF, Battistini L. IL-12-mediated NKRP1A up-regulation and consequent enhancement of endothelial transmigration of V delta 2+ TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients. J Immunol 1999 Apr 1;162(7):4349-54
5.646
88. Rubartelli A, Poggi A, Sitia R, Zocchi MR. Reply to reinhold et al Immunol Today 1999 Aug;20(8):384-5
9.480
89. Gardella S, Andrei C, Costigliolo S, Poggi A, Zocchi MR, Rubartelli A. Interleukin-18 synthesis and secretion by dendritic cells are modulated by interaction with antigen-specific T cells. J Leukoc Biol 1999 Aug;66(2):237-41
4.403
90. Ferrero E, Vettoretto K, Bondanza A, Villa A, Resnati M, Poggi A, Zocchi MR. uPA/uPAR system is active in immature dendritic cells derived from CD14+CD34+ precursors and is down-regulated upon maturation. J Immunol 2000 Jan 15;164(2):712-8
5.646
9**1.** Gardella S, Andrei C, Poggi A, Zocchi MR, Rubartelli A. Control of interleukin-18 secretion by dendritic cells: role of calcium influxes. FEBS Lett 2000 Sep 22;481(3):245-8
3.541
92. Poggi A, Pellegatta F, Leone BE, Moretta L, Zocchi MR. Engagement of the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias. Eur J Immunol 2000 Oct;30(10):2751-8
5.179
93. Poggi A, Spaggiari GM, Quintino S, Setti M, Pierri I, Indiveri F, Gobbi M, Moretta L, Zocchi MR. Engagement of the Leukocyte-Associated Ig-like Receptor –1 induces programmed prevents proliferation and induces apoptosis in human acute myeloid leukemias. Haematologica, 2000; 85:54.
6.416
94. Spaggiari GM, Carosio R, Pende D, Marcenaro S, Rivera P, Zocchi MR, Moretta L, Poggi A.
NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur J Immunol 2001 Jun;31(6):1656-65
5.179
95. Gardella S, Andrei C, Lotti LV, Poggi A, Torrisi MR, Zocchi MR, Rubartelli A. CD8(+) T lymphocytes induce polarized exocytosis of secretory lysosomes by dendritic cells with release of interleukin-1beta and cathepsin D. Blood 2001 Oct 1;98(7):2152-9
10.555

96. Zocchi MR, Pellegatta F, Pierri I, Gobbi M, Poggi A. Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells. Eur J Immunol 2001 Dec;31(12):3667-75
5.179
97. Poggi A, Carosio R, Spaggiari GM, Fortis C, Tambussi G, Dell'Antonio G, Dal Cin E, Rubartelli A, Zocchi MR. NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J Immunol 2002 Jan 1;168(1):95-101
5.646
98. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002 Jan;23(1):14-8
9.480
99. Spaggiari GM, Contini P, Carosio R, Arvigo M, Ghio M, Oddone D, Dondero A, Zocchi MR, Puppo F, Indiveri F, Poggi A. Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood 2002 Mar 1;99(5):1706-14
10.555
100. Poggi A, Carosio R, Rubartelli A, Zocchi MR. Beta(3)-mediated engulfment of apoptotic tumor cells by dendritic cells is dependent on CAMKII: inhibition by HIV-1 Tat. J Leukoc Biol 2002 Mar;71(3):531-7
4.403
101. Poggi A, Zocchi MR, Carosio R, Ferrero E, Angelini DF, Galgani S, Caramia MD, Bernardi G, Borsellino G, Battistini L. Transendothelial migratory pathways of V delta 1+TCR gamma delta+ and V delta 2+TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II. J Immunol 2002 Jun 15;168(12):6071-7
5.646
102. Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F, Zocchi MR, Poggi A. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 2002 Dec 1;100(12):4098-107
10.555
103. Ferrero E, Belloni D, Contini P, Foglieni C, Ferrero ME, Fabbri M, Poggi A, Zocchi MR.
Transendothelial migration leads to protection from starvation-induced apoptosis in CD34+ CD14+ circulating prescursors: evidence for PECAM-1 involvement through Akt/PKB activation. Blood. 2003 Jan 1;101(1):186-93. Epub 2002 Aug 15.
10.555
104. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppp P. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK $CD8^+$ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol. 2003 Jan;33(1):125-34.
5.179
105. Poggi A, Carosio R, Fenoglio D, Brenci S, Murdaca G, Setti M, Indiveri F, Scabini S, Ferrero E, Zocchi MR. Migration of V{delta}1 and V{delta}2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1 infected patients: competition by HIV-1 TAT.Blood. 2003 Nov 20
10.555
106. Spaggiari GM, Contini P, Negrini S, Dondero A, Carosio R, Ghio M, Puppo F, Indiveri F, Zocchi MR, Poggi A. IFN-gamma production in human NK cells through the engagement of CD8 by soluble or surface HLA class I molecules. Eur J Immunol. 2003 Nov;33(11):3049-59.
5.179
107. Spaggiari, G.M., P. Contini, M.R. Zocchi, and A. Poggi. Interaction of solubile HLA-I antigens with either CD8 or activating isoform of the inhibitory Receptor Superfamily members induces apoptosis of human NK cells via FasL/Fas interaction. Research Trends in Immunology, 2003, vol 5, 33-43.
NI

108. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A.Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9745-50. Epub 2004 Jun 10.
9.432
109. Zocchi M.R., and A. Poggi, Role of gammadelta T lymphocytes in tumor defense. Frontiers in Bioscience. 2004, 9:2588-2604.
3.736
110. M.R.Zocchi and A.Poggi PECAM-1, apoptosis and $CD34^+$ precursors. Leukemia and Lymphoma 2004, 45:2205-2213.
2.397
111. Poggi A, Venturino C, Castellani S., Clavio M., Miglino M., Gobbi M., Steinle A.,Ghia P., Stella S., Caligaris Cappio F., and Zocchi MR. V◎1 T lymphocytes from B-CLL patients recognise ULBP3 expressed on leukemic B cells and upregulated by transretinoic acid. Cancer Research 2004, 64:9172-9179.
7.543
112. Ropoli M, Geroldi A, Rossi O, Degan P, Zupo S, Poggi A, Frosina G. Expression of the Drosophila melanogaster S3 ribosomal/repair protein in T24 human bladder cells. Anticancer Res. 2004 Nov-Dec;24(6):3811-8.
1.428
113. Poggi A., A-M Massaro, S. Negrini, P. Contini, and MR. Zocchi. Tumor-induced apoptosis of human IL2 activated Natural Killer cells. Role of Natural Cytotoxicity Receptors. J. Immunol. 174:2656-2660, 2005.
5.646
114. M.R. Zocchi and A. Poggi. Editorial: Innate immunity and cytokines: how to regulate host response against pathogens avoiding autoreactivity. Curr. Med. Chem. (CMC-AIAA) 2005, 4:113-114.
4.944
115. M.R. Zocchi and A. Poggi Triggering of apoptosis and pro-inflammatory cytokines in NK cells: regulation by cyclosporin A. Curr. Med. Chem. (CMC-AIAA) 2005, 4:115-120.
4.944
116. Chan W.L., N. Pejnovic, H. Hamilton, T.V.Liew, D. Popadic, A. Poggi, and S.M. Khan. Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT and Th cells. Circ. Res. 2005, 96:675-683.
9.214
117. Semino C., G. Angelini, A. Poggi and A. Rubartelli. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the Dc maturation factor HMGB1. Blood 2005, Jul 15;106(2):609-16.
10.555
118. Zocchi M.R., P. Contini , M. Alfano and A. Poggi. Pertussi toxin (PTX) B subunit and the non-toxic PTX mutant PT9K/129G inhibit Tat-induced TGF◎◎ production by NK cells and TGF-◎-mediated NK cell apoptosis. J. Immunol. 2005, 174:6054-6061.
5.646
119. Poggi A., S. Negrini, M.R. Zocchi, A-M Massaro, L. Gargiulo, R. Notaro and L. Luzzatto. Patients with Paroxysmal Nocturnal Hemoglobinuria have a high frequency of peripheral blood T cells expressing activating isoforms of Inhibiting Superfamily Receptors. Blood 2005, 106:2399-2408.
10.555
120. Poggi A, Contini P, Castellani S, Setti M, Murdaca G and Zocchi MR. Regulation of ◎◎ T cell survival by soluble HLA-I: Involvement of CD8 and killer Ig-like receptors. Eur. J. Immunol. 2005, 35:2670-2678.
5.179
121. Poggi A, Prevosto C, Massaro A-M, Negrini S, Urbani S, Saccardi R, Pierri I, Gobbi M and Zocchi MR. Interaction between human natural killer cells and bone marrow stromal cells induces NK cell triggering. Role of NKp30 and NKG2D receptors. J. Immunol. 2005, Nov 15;175(10):6352-60.
5.646
122. Poggi A. and Zocchi MR. Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells. Autoimmun Rev. 2005 Nov;4(8):532-6. Review

6.368

123. Contini P., M. Ghio, A. Merlo, A. Poggi, F. Indiveri and F. Puppo. Apoptosis of antigen specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas-ligand/Fas mediated. Evidence for the involvement of $p56^{lck}$, calcium calmodulin kinase II and PKC-theta signalling pathways and for NF-kB and NF-AT nuclear translocation. J. Immunol. 2005, Dec 1;175(11):7244-54.

5.646

124. Ropolo M, Geroldi A, Degan P, Andreotti V, Zupo S, Poggi A, Reed A, Kelley MR, Frosina G. Accelerated repair and reduced mutagenicity of oxidative DNA damage in human bladder cells expressing the E. coli FPG protein. Int J Cancer. 2005 Oct 10; [Epub ahead of print]

4.722

125. Scielzo C., Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi MR, Chilosi M, Caligaris-Cappio F, and Ghia P. Human normal mature B lymphocytes express the T-lymphocyte-related tyrosine kinase ZAP-70. 2006 Leukemia 2006 Apr;20(4):689-95.

8.296

126. Poggi A. and Zocchi MR. Antigen presenting cells and stromal cells trigger human natural killer lymphocytes to autoreactivity: evidence for the involvement of natural cytotoxicity receptors (NCR) and NKG2D. Clinical and Developmental Immunology, 2006 Jun-Dec;13(2-4):325-36. Review.

3.000

127. Poggi A. and Zocchi MR Human natural killer lymphocytes through the engagement of natural cytotoxicity receptors and NKG2D can trigger self aggression. Autoimmun. Rev. 6:295/299, 2007

6.368

128. Poggi A and Zocchi MR. HIV-1 tat triggers TGFβ production and NK cell apoptosis that is prevenrted by pertussis toxin B. Clinical and Developmental Immunology 2006 Jun-Dec;13(2-4):369-72.

3.000

129. Catellani S, Poggi A. Bruzzone A., P. Dadati, J-L- Ravetti, Gobbi M., and Zocchi M.R. Expression of UL-16 binding proteins on neoplastic B cells and expansion of γδT lymphocytes in low grade non Hodgkin lymphomas. 2006, Blood. 2007 Mar 1;109(5):2078-85. Epub 2006 Sep 14.

10.555

130. Contini P, Zocchi MR, Pierri I, Albarello A, Poggi A. In vivo apoptosis of CD8(+) lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand. Leukemia. 2007 Feb;21(2):253-60. Epub 2006 Dec 14.

8.296

131. Venè R., Arena G., Poggi A., D'Arrigo C., Mormino M., Noonan D.M., Albini A. and Tosetti T. Novel cell death pathways induced by N/(4/hydroxyphenyl)retinamide: therapeutic implications. Mol. Cancer Ther. 6:286/298, 2007

4.953

132. Ropolo M., Degan P., Foresta M., D'errico M., Lasiglie D., Dogliotti E., Casartelli G., Zupo S., Poggi A., and Frosina G. Complementation of the oxidative damage DNA repair defect in Cockayne sindrome A and B cells by E. coli formamidopyrimidine DNA glycosilase. Free Radic Biol Med. 2007 Jun 15;42(12):1807-17. Epub 2007 Mar 12.

6.081

133. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A.Generation of $CD4^+$ or $CD8^+$ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007 Jul;92(7):881-8.

6.416

134. Poggi A, Prevosto C, Zancolli M, Canevali P, Musso A, Zocchi MR. NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells. Ann N Y Acad Sci. 2007 Aug;1109:47-57.

2.670

135. Poggi A, Zancolli M, Castellani S, Borsellino G, Battistini L, Zocchi MR. Migratory pathways of gammadelta T cells and response to CXCR3 and CXCR4 ligands: adhesion molecules involved and implications for multiple sclerosis pathogenesis. Ann N Y Acad Sci. 2007 Jun;1107:68-78.

2.670

136. Poggi A., Castellani C., Fenoglio D., Borsellino G., Battistini L., and Zocchi M.R. Adesion molecules and kinases involved in ◎◎ T cells migratory pathways: implications for viral and autoimmune diseases. Curr. Med. Chem. (CMC-AIAA), 2007, 14, 3166-3170.
4.708

137. Lombardi M.L., Terrazzano G., Casentini E., Gargiulo L., Risitano A., Camerlengo R., Sica M., Aufiero D., Poggi A., Dirozzi G., Luzzatto L., Rotoli B., Notaro R. , Alfinito F. and Ruggiero G. Paroxysmal nocturnal hemoglobinuria: Significant association with specific HLA-A, -B, -C, and -DR alleles in an Italian population. Human Immunol. 2008. 69, 202-206.
3.852

138. Poggi A., Catellani S., Bruzzone A., Caligaris-Cappio F., Gobbi M. and Zocchi M.R. Lack of the Leukocyte-associated Ig-like receptor-1 expression in high risk chronic lymphocytic leukemias results in the absence of a negative signal regulating kinase activation and cell division. Leukemia. 2008 May;22(5):980-8. Epub 2008 Feb 21.
8.296

139. Viale M., Petrillo M., Taccagno M., Castagnola P., Aiello C., Cordazzo C. Mariggiò M.A., Jadhav S.A., Bianchi L., Leto G., Rizzato E., Poggi A., and Spinelli D. Sensitivity of different resistant tumour cell lines to the two novel compounds (2*Z*,4*E*)-2-methylsulfanyl-5-(1-naphthyl)-4-nitro-2,4-pentadienoate and (1*E*,3*E*)-1,4-bis(2-naphthyl)-2,3-dinitro-1,3-butadiene. Eur J Pharmacol. 2008 Jun 24;588(1):47-51. Epub 2008 Apr 12.
2.522

140. Patterson S., Chaidos A., Neville D CA, Poggi A, Butters T, Roberts I . A.G., and Karadimitris A. Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer immunoglobulin receptors. J. Immunol, 2008 Sep 1;181(5):3268-76.
5.646.

141. Poggi A,and Zocchi MR. Role of bone marrow stromal cells in the generation of human CD8(+) regulatory T cells. Hum Immunol. 2008 Nov;69(11):755-9. Epub 2008 Sep 24. Review.
3.852

142. Ponassi R, Biasotti B, Tomati V, Bruno S, Poggi A, Malacarne D, Cimoli G, Salis A, Pozzi S, Miglino M, Damonte G, Cozzini P, Spyraki F, Campanini B, Bagnasco L, Castagnino N, Tortolina, M, Mumot A, Frassoni F, Daga A, Cilli M, Piccardi F, Monfardini I, Perugini M, Zoppoli G, D'Arrigo C, Pesenti R, and Parodi S. A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle. 2008 Oct;7(20):3211-24. Epub 2008 Oct 20.
4.087

143. Poggi A., S. Catellani, A. Garuti, I. Pierri, M. Gobbi, and M. R. Zocchi. Effective in vivo induction of NKG2D ligands in acute myeloid leukemias by all-transretinoic acid and sodium valproate. Leukemia. 2009 Jan 8.
8.296

144. Ropolo M., Daga A., Griffero F., Foresta M., Casartelli G.L., Zumino A., Poggi A., Cappelli E., Zona GL., Spaziante R., Corte G., and Frosina G. A comparative analysis of DNA repair in stem and non-stem glioma cell cultures. Mol Cancer Res. 2009 Mar;7(3):383-92. Epub 2009 Mar 10.
4.162

145. Fenoglio D, A. Poggi, S. Catellani, F. Battaglia, Al. Ferrera, M. Setti, G. Murdaca, and M.R. Zocchi Vγ1 T lymphocytes producing IFNγ and IL-17 are expanded in HIV-1 infected patients and respond to Candida albicans. Blood 2009 Jun 25;113(26):6611-8. Epub 2009 Apr 24
10.555

146. Ghio M., Contini P., Negrini S., Boero S., Musso A., and Poggi A. Soluble HLA-I-mediated secretion of TGF-β1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J. Immunol, 2009 Oct 14.
5.179

147. Poggi A., Castellani, S., Musso, A., and Zocchi M.R. Gammadelta T lymphocytes producine IFN-γ and IL-17 in response to Candida albicans or Mycobacterial antigens: possible implications for acute and chronic inflammation.. Curr Med Chem. 2009;16(35):4743-9.
4.843.

148. Bruzzone S., Frusciane F., Morando S., Ferrando T., Poggi A., Garuti A., D'Urso A., Selmo M., Soncini D, Benvenuto F., Cea M., Zoppoli G., Moran E., Ballestrero A., Sordat B., Patrone F.,Mostoslavsky R., Uccelli A., and Nencioni A. Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. PLoS One. 2009 Nov 19;4(11):e7897.
4.351

149. Foresta M., Ropolo M., Degan P., Pettinati I., Kow IW., Damonte G., Poggi A. and Frosina G. Defective Repair of 5-Hydroxy2'deoxycytidine in Cockayne Syndrome Cells and its Complementation by E.coli Formamidopyrimidine DNA Glycosylase and Endonuclease III. Free Radic Biol Med. 2010 Mar 1;48(5):681-90. Epub 2009 Dec 21.
5.399

150. Poggi A., Musso A., Boero S., Canevali P., and Zocchi M.R. Statins as either immunomodulators or anti-cancer drugs: functional activities on tumor stromal cells and natural killer cells. CMCAIAA, 2010, 9,82-92.
NI

151. Poggi A., Prevosto C., Catellani S., Rocco I., Garuti A., and Zocchi M.R. Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. Br J Haematol. 2010 Nov;151(3):252-64. doi: 10.1111/j.1365-2141.2010.08343.x. Epub 2010 Aug 31
4.597.

152. Poggi A., Zancolli M., Catellani S., Boero S., Musso A., and Zocchi MR. Differential survival of ◎◎T cells, ◎◎T cells, and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells. International Journal of Cancer, 2011 Jul 15;129(2):387-96. doi: 10.1002/ijc.25682. Epub 2010 Nov 3.
4.722.

153. Musso A., Zocchi MR., and Poggi A. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T cell proliferation and B cell survival. Haematologica, 2011 Jan;96(1):16-23. Epub 2010 Sep 30
6.416.

154. Ghio M., Contini P., Negrini S., Mazzei C., Zocchi MR., and Poggi A. Down-regulation of human Natural Killer cell-mediated cytolysis induced by blood transfusion: role of transforming growth factor◎◎,◎◎soluble◎Fas ligand and soluble class I human leukocyte antigen. Transfusion, 2011 Jul;51(7):1567-73. doi: 10.1111/j.1537-2995.2010.03000.x. Epub 2011 Jan 7.
2.982.

155. Mirabella T., Poggi A., Scaranari M., Mogni M., Lituania M., Baldo C., Cancedda R., Gentili C. Phenotypic characterization of Human Amniotic Fluid Stem Cells (hAFSCs): recruitment of host's progenitor cells after in vivo implantation. Biomaterials 2011 Jun;32(18):4218-27. Epub 2011 Apr 2.
7.365

156. M. Ropolo, E. Cappelli, M. Foresta, A. Poggi, L. Proietti-De-Santis and G. Frosina. Detective resolution of pH2AX foci and enhanced DNA breackage in ionizing radiation-treated Cockayne syndrome B cells. IUBMB Life, 2011 Apr;63(4):272-6. doi: 10.1002/iub.445. Epub 2011 Mar 24
3.578

157. S. Catellani, I. Pierri, M. Gobbi, A. Poggi and M.R. Zocchi. Imatinib mesylate treatment increases $CD5^+$ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in the bone marrow of patients with chronic myelogenous leukemia. PLoS One. 2011 Apr 18;6(4):e18925.
4.351

158. Fenoglio D, Zocchi MR, Parodi A, Durando P, Gabutitp G, Gasparini R, Poggi A. MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. J Prev Med Hyg. 2011 Sep;52(3):137-41.
NI

159. MR Zocchi, S. Catellani, P. Canevali, S. Tavella, A. Garuti, B. Villaggio, A. Zunino, M. Gobbi[6], Giulio Fraternali-Orcioni, Annalisa Kunkl, Jean-Louis Ravetti, Silvia Boero, Alessandra Musso, and Alessandro Poggi. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D-Ligands recognition in Hodgkin lymphomas. Blood, 2012 Feb 9;119(6):1479-89.
doi: 10.1182/blood-2011-07-370841. Epub 2011 Dec 13.
10.558

160. A. Poggi and M.R. Zocchi Modulating mesenchymal stromal cell function with cholesterol synthesis inhibitors. CMC (Current Medicinal Chemistry). Curr Med Chem. 2011;18(34):5196-205.
4.630

161. Zocchi MR, Poggi A.Targeting the microenvironment in hematological malignancies: how to condition both stromal and effector cells to overcome cancer spreading. Curr Med Chem. 2011;18(34):5172-3.
4.630

162. A. Poggi, P. Canevali, M. Contatore, and G. Ciprandi. Higher frequencies of $CD161^{+}$ circulating T lymphocytes in allergic rhinitis patients than in healthy donors. International Archives of Allergy and Immunology, Int Arch Allergy Immunol. 2012 Jan 25;158(2):151-156.
2.235

163. A. Raso, D. Vecchio, E. Cappelli, M. Ropolo, A. Poggi, P. Nozza, R. Biassoni, S. Mascelli, V. Capra, F. Kalfas, P. Severi, and G. Frosina. Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double strand breaks-inducing agents by pharmacological inhibition of Ataxia Telangiectasia Mutated protein. Brain Pathology, Brain Pathol. 2012 Jan 18. doi: 10.1111/j.1750-3639.2012.00566.
4.741

165. Colombo BM, Canevali P, Magnani O, Rossi E, Puppo F, Zocchi MR, Poggi A. Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients. PLoS One. 2012;7(2):e31903. Epub 2012 Feb 15.
4.441

166. E. Boggio; M. Melensi; S. Bocca; A. Chiocchetti; C. Comi; N. Clemente; E. Orilieri; M. F. Soluri; S. D'Alfonso; R. Mechelli; G. Gentile; A. Poggi; M. Salvetti; U. Ramenghi and U. Dianzani. The -346T Polymorphism of the SH2D1A gene is associated with development of autoimmunity/lymphoproliferation in males with defective Fas function. Hum Immunol. 2012 May;73(5):585-92. doi: 10.1016/j.humimm.2012.02.025. Epub 2012 Mar 7
2872

167. F. Montecucco, I. Bauer, V. Braunersreuther, S. Bruzzone, A. Poggi, E. Mannino, G. Pelli, K. Galan, M. Bertolotto, S. Lenglet, C. Montessuit, R. Lerch, C. Pellieux, A. Garuti, F. Dallegri, R. Mostoslavsky, F. Patrone, F. Mach, A. Nencioni. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (Nampt) reduces neutrophil-mediated injury in a mouse model of myocardial ischemia/reperfusion (I/R). Antioxid Redox Signal. 2013 Feb 20;18(6):630-41. doi: 10.1089/ars.2011.4487. Epub 2012 May 14.
8.209

168. Magnone M, Bauer I, Poggi A, Mannino E, Sturla L, Brini M, Zocchi E, De Flora A, Nencioni A, Bruzzone S. NAD+ levels control Ca2+ stores replenishment and mitogen-induced increase of cytosolic Ca2+ by ADPR-dependent TRPM2 gating in human T lymphocytes. J Biol Chem. 2012 Jun 15;287(25):21067-81. doi: 10.1074/jbc.M111.324269. Epub 2012 Apr 30
5.328

169. Poggi A, Zocchi MR.Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.Oncoimmunology. 2012 Mar 1;1(2):214-216.
6.283

170. Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, Zoppoli G, Cea M, Feldmann G, Mostoslavsky R, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses.J Biol Chem. 2012 Nov 30;287(49):40924-37. doi: 10.1074/jbc.M112.405837. Epub 2012 Oct 18.
5.328

171. Penna I, Vassallo I, Nizzari M, Russo D, Costa D, Menichini P, Poggi A, Russo C, Dieci G, Florio T, Cancedda R, Pagano A. A novel snRNA-like transcript affects amyloidogenesis and cell cycle progression through perturbation of Fe65L1 (APBB2) alternative splicing. Biochim Biophys Acta. 2013 Jun;1833(6):1511-26. doi: 10.1016/j.bbamcr.2013.02.020. Epub 2013 Feb 26.
5.083

172. Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, Minghelli S, Morabito A, Fontana V, Pietra G, Carrega P, Ferrari N, Tosetti F, Chang LJ, Mingari MC, Ferlazzo G, Poggi A, Pistillo MP. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J Transl Med. 2013 May 1;11(1):108. [Epub ahead of print].
3.47

173. Poggi A, Boero S, Musso A, Zocchi MR. Selective role of mevalonate pathway in regulating perforin but not FasL and TNF◎ release in human natural killer cells. PLoS One. 2013 May 7;8(5):e62932. doi: 10.1371/journal.pone.0062932. Print 2013.
3.730

174. Amaro A, Mirisola V, Angelini G, Musso A, Tosetti F, Esposito AI, Perri P, Lanza F, Nasciuti F, Mosci C, Puzone R, Salvi S, Truini M, Poggi A, Pfeffer U. Evidence of EGFR Signaling in Uveal Melanoma, Its inhition by Gefitinib and Cetuximab Mediated Antibody-Dependent Cellular Cytotoxicity. Eur J Cancer. 2013 Jul 9. doi:pii: S0959-8049(13)00486-3. 10.1016/j.ejca.2013.06.011. [Epub ahead of print]
4.781

175. Poggi A and Zocchi MR. Stress immunity in lymphomas: mesenchymal cells as a target of therapy. Front Biosci (Landmark Ed). 2014 Jan 1;19:281-90
3.736

176. Musso A., Catellani S., Canevali P.,Tavella S., Venè R., Boero S., Pierri I., Gobbi M., Kunkl A., Ravetti J-L, Zocchi MR. and Poggi A. Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vdelta 2 T lymphocytes in non-Hodgkin lymphomas. Haematologica/the Hematology Journal, 2014 Jan;99(1):131-9. doi: 10.3324/haematol.2013.097311. Epub 2013 Oct 25
6.416

177. Scabini S, Montecucco F, Nencioni A, Zoppoli G, Sartini M, Rimini E, Massobrio A, De Marini L, Poggi A, Boaretto R, Romairone E, Ballestrero A, Ferrando V. The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer. World J Surg Oncol. 2013 Nov 18;11:292. doi: 10.1186/1477-7819-11-292. 24246069.
NI

178. Vecchio D, Daga A, Carra E, Marubbi D, Baio G, Neumaier CE, Vagge S, Corvò R, Pia Brisigotti M, Louis Ravetti J, Zunino A, Poggi A, Mascelli S, Raso A, Frosina G. Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019. Int J Cancer. 2013 Dec 19. doi: 10.1002/ijc.28680. [Epub ahead of print] in the press.
6.198

179. Giuliani M, Poggi A, Bennaceur Griscelli A, and Lataillade JJ. IFNGamma Priming Protects Fetal and Embryonic MSC from NK Cell-Mediated Killing and Improves their Immunosuppressive Properties: Role of Activating and Inhibitory Receptors. J Cell Sci Ther 2014, 5:3
4.203

180. Poggi A, and ZocchiMR. NK cell autoreactivity and autoimmune diseases. Front Immunol. 2014 Feb 4;5:27. doi: 10.3389/fimmu.2014.00027. eCollection 2014. Review
NI

181. Poggi A, Zocchi MR. How to exploit stress-related immunity against Hodgkin's lymphoma: Targeting ERp5 and ADAM sheddases. Oncoimmunology. 2013 Dec 1;2(12):e27089. Epub 2013 Dec 5. Review.
6.293

182. Foresta M, Izzotti A, La Maestra S, Micale R, Poggi A, Vecchio D, Frosina G. Accelerated Repair and Reduced Mutagenicity of DNA Damage Induced by Cigarette Smoke in Human Bronchial Cells Transfected with E.coli Formamidopyrimidine DNA Glycosylase. PLoS One. 2014 Jan 31;9(1):e87984. doi: 10.1371/journal.pone.0087984. eCollection 2014.
3.730

183. Poggi A, Musso A, Dapino I, Zocchi MR. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett. 2014 May-Jun;159(1-2):55-72. doi: 10.1016/j.imlet.2014.03.001. Epub 2014 Mar 20.
2.337

184. Venè R, Cardinali B, Arena G, Ferrari N, Benelli R, Minghelli S, Poggi A, Noonan DM, Albini A, Tosetti F. Glycogen Synthase Kinase 3 Regulates Cell Death and Survival Signaling in Tumor Cells under Redox Stress. Neoplasia. 2014 Sep;16(9):710-22. doi: 10.1016/j.neo.2014.07.012.
5.398

185. Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, Mastracci L, Boero S, Montecucco F, Sociali G, Lasigliè D, Damonte P, Grozio A, Mannino E, Poggi A, D'Agostino VG, Monacelli F, Provenzani A, Odetti P, Ballestrero A, Bruzzone S, Nencioni A.Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity. J Biol Chem. 2014 Dec 5;289(49):34189-204. doi: 10.1074/jbc.M114.594721. Epub 2014 Oct 20
4.600

186. Poggi A, Zocchi MR. γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.Front Immunol. 2014 Nov 11;5:575.
NI

187. Poggi A, Zocchi MR. Mesenchymal stromal cells as regulators of anti-tumour immune response. Indian J Med Res. 2015 Feb;141(2):139-42
1.396

188. Montecucco F, Lenglet S, Carbone F, Boero S, Pelli G, Burger F, Roth A, Bertolotto M, Nencioni A, Cea M, Dallegri F, Fraga-Silva RA, Fougère L, Elfakir C, Gassner AL, Rudaz S, Parissaux X, Wils D, Salomé M, Vuilleumier N, Poggi A, Mach F. Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vascul Pharmacol. 2015 Apr 25.
3.635

189. Venè R, Tosetti F, Minghelli S, Poggi A, Ferrari N, Benelli R. Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation. Oncotarget. 2015 May20;6(14):12310-25.
6.627

190. Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D'Alonzo A, Romani M, Del Mastro M, Poggi A, Pistillo MP. Analysis of *in vitro* ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J.Transl Med. 2015 Oct 8;13(1):324. doi: 10.1186/s12967-015-0680-0.
3.93.

191. Muraglia A, Todeschi MR, Papait A, Poggi A, Spanò R, Strada P, Cancedda R, Mastrogiacomo M. Combined platelet and plasma derivatives enhance proliferation of stem/progenitor cells maintaining their differentiation potential. Cytotherapy. 2015 Dec;17(12):1793-806. doi: 10.1016/j.jcyt.2015.09.004. PMID: 26589754

192. Zocchi MR, Camodeca C, Nuti E, Rossello A, Venè R, Tosetti F, Dapino I, Costa D, Musso A, Poggi A. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunology. 2015 Dec 29;5(5):e1123367. doi: 10.1080/2162402X.2015.1123367. eCollection 2016 May.
6.283

193. Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A. Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models. Eur J Med Chem. 2016 Mar 23;111:193-201. doi: 10.1016/j.ejmech.2016.01.053. Epub 2016 Jan 29.
3.902.

194. Poggi A, Giuliani M. Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. Vaccines (Basel). 2016 Nov 8;4(4). pii: E41.
NI.

195. Penna I, Gigoni A, Costa D, Vella S, Russo D, Poggi A, Villa F, Brizzolara A, Canale C, Mescola A, Daga A, Russo C, Nizzari M, Florio T, Menichini P, Pagano A. The inhibition of 45A ncRNA expression reduces tumor formation, affecting tumor nodules compactness and metastatic potential in neuroblastoma cells. Oncotarget. 2016 Dec 24. doi: 10.18632/oncotarget.14138. [Epub ahead of print] PMID:28029658

5.008.

196. Papait A, Cancedda R, Mastrogiacomo M, Poggi A. Allogeneic platelet-rich plasma affects monocyte differentiation to dendritic cells causing an anti-inflammatory microenvironment putatively fostering the wound healing. J Tissue Eng Regen Med. 2016 Nov 15. doi: 10.1002/term.2361. [Epub ahead of print] PMID:27863082

5.199.

197. Pereira RC, Martinelli D, Cancedda R, Gentili C, Poggi A. Human Articular Chondrocytes Regulate Immune Response by Affecting Directly T Cell Proliferation and Indirectly Inhibiting Monocyte Differentiation to Professional Antigen-Presenting Cells. Front Immunol. 2016 Oct 24;7:415.PMID:27822208

5.695.

198. Roncella S, Laurent S, Fontana V, Ferro P, Franceschini MC, Salvi S, Varesano S, Boccardo S, Vigani A, Morabito A, Canessa PA, Giannoni U, Rosenberg I, Valentino A, Fedeli F, Merlo DF, Ceppi M, Riggio S, Romani M, Saverino D, Poggi A, Pistillo MP. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.Cancer Immunol Immunother. 2016 Aug;65(8):909-17. doi: 10.1007/s00262-016-1844-3.

4.846

199. Lasigliè D, Boero S, Bauer I, Morando S, Damonte P, Cea M, Monacelli F, Odetti P, Ballestrero A, Uccelli A, Mostoslavsky R**,** Poggi A, Nencioni A. Sirt6 regulates dendritic cell differentiation, maturation, and function.Aging (Albany NY). 2016 Jan;8(1):34-49.PMID:26761436.

6.432.

200. Garbati P, Ravera S, Scarfì S, Salis A, Rosano C, Poggi A, Damonte G, Millo E, Balestrino M. Effects on Energy Metabolism of Two Guanidine Molecules, $(Boc)_2$ -Creatine and Metformin. J Cell Biochem. 2017 Jan 27. doi: 10.1002/jcb.25914. [Epub ahead of print] PMID:28128472.

3.446.

201. Zocchi MR, Costa D, Venè R, Tosetti F, Ferrari N, Minghelli S, Benelli R, Scabini S, Romairone E, Catellani S, Profumo A, and Poggi A. Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with anti-tumor activity. Accepted author version posted online: 06 Jan 2017.

6.266.

202. Balza E, Zanellato S, Poggi A, Reverberi D, Rubartelli A, Mortara L. The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells. Eur J Immunol. 2017 Apr;47(4):743-753. doi: 10.1002/eji.201646544. Epub 2017 Mar 6. PMID: 2819854.

4.227

203. Brizzolara A, Benelli R, Venè R, Barboro P, Poggi A, Tosetti F, Ferrari N. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. Cancer Lett. 2017 Aug 1;400:9-17. doi: 10.1016/j.canlet.2017.04.025. Epub 2017 Apr 25. PMID:28450158.

6.375

204. Damonte P, Sociali G, Parenti MD, Soncini D, Bauer I, Boero S, Grozio A, Holtey MV, Piacente F, Becherini P, Sanguineti R, Salis A, Damonte G, Cea M, Murone M, Poggi A, Nencioni A, Del Rio A, Bruzzone S. SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. Bioorg Med Chem. 2017 Oct 15;25(20):5849-5858. doi: 10.1016/j.bmc.2017.09.023. Epub 2017 Sep 19. PMID:28958848.

2.454

205. Tosetti F, Venè R, Camodeca C, Nuti E, Rossello A, D'Arrigo C, Galante D, Ferrari N, Poggi A, Zocchi MR. Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells. Oncoimmunology. 2018 Jan 19;7(5):e1421889. doi: 10.1080/2162402X.2017.1421889. eCollection 2018. PMID:29721369.

7.719

206. Varesano S, Zocchi MR, Poggi A. Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures. Front Immunol. 2018 May 8;9:998. doi: 10.3389/fimmu.2018.00998. eCollection 2018. Erratum in: Front Immunol. 2018 Jun 13;9:1343.

5.695

207. Mortara L, Balza E, Bruno A, Poggi A, Orecchia P, Carnemolla B. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy. Front Immunol. 2018 Dec 18;9:2905. doi: 10.3389/fimmu.2018.02905. eCollection 2018. Review. PMID: 30619269.

5.695

208. Balza E, Carnemolla B, Orecchia P, Rubartelli A, Poggi A, Mortara L. Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency. Curr Med Chem. 2018 Sep 4. doi: 10.2174/0929867325666180904121118. [Epub ahead of print]PMID:30182839.

3.469

209. Pistillo MP, Carosio R, Banelli B, Morabito A, Mastracci L, Ferro P, Varesano S, Venè R, Poggi A, Roncella S. IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade. Cell Mol Immunol. 2019 Jun 19. doi: 10.1038/s41423-019-0245-x. [Epub ahead of print] No abstract available. PMID:31217525.

8.213

210. D'Andrea F, Nuti E, Becherini S, Cuffaro D, Husanu E, Camodeca C, De Vita E, Zocchi MR, Poggi A, D'Arrigo C, Cappello V, Gemmi M, Nencetti S, Chiappe C, Rossello A. Design and Synthesis of Ionic Liquid-Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI-Coated Gold Nanoparticles. ChemMedChem. 2019 Mar 22;14(6):686-698. doi: 10.1002/cmdc.201800733. Epub 2019 Feb 14. PMID:30600908.

3.469

211. Saint-Martin A, Martínez-Ríos J, Castañeda-Patlán MC, Sarabia-Sánchez MA, Tejeda-Muñoz N, Chinney-Herrera A, Soldevila G, Benelli R, Santoyo-Ramos P, Poggi A, Robles-Flores M. Functional Interaction of Hypoxia-Inducible Factor 2-Alpha and Autophagy Mediates Drug Resistance in Colon Cancer Cells. Cancers (Basel). 2019 May 30;11(6). pii: E755. doi: 10.3390/cancers11060755.PMID:31151160.

6.072

212. Poggi A, Benelli R, Venè R, Costa D, Ferrari N, Tosetti F, Zocchi MR. Human Gut-Associated Natural Killer Cells in Health and Disease. Front Immunol. 2019 May 3;10:961. doi: 10.3389/fimmu.2019.00961. eCollection 2019. Review. PMID: 31130953.

4.716

213. Bassani B, Baci D, Gallazzi M, Poggi A, Bruno A, Mortara L. Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects. Cancers (Basel). 2019 Apr 1;11(4). pii: E461. doi: 10.3390/cancers11040461. Review. PMID:30939820.

6.072

214. Carbone F, Dallegri F, Montecucco F, Poggi A, Nobili FM, Cacciapaglia F, Afeltra A, Moccetti T, Colombo BM. Serum osteopontin negatively impacts on intima-media thickness in patients with systemic lupus erythematosus. Eur J Clin Invest. 2019 May;49(5):e13089. doi: 10.1111/eci.13089. Epub 2019 Mar 3.PMID:30767212.

3.086.

215. Poggi A, Benelli R, Venè R, Costa D, Ferrari N, Tosetti F, Zocchi MR. Human Gut-Associated Natural Killer Cells in Health and Disease. Front Immunol. 2019 May 3;10:961. doi: 10.3389/fimmu.2019.00961. eCollection 2019. Review.PMID:31130953

4.716

216. Saint-Martin A, Martínez-Ríos J, Castañeda-Patlán MC, Sarabia-Sánchez MA, Tejeda-Muñoz N, Chinney-Herrera A, Soldevila G, Benelli R, Santoyo-Ramos P, Poggi A, Robles-Flores M. Functional Interaction of Hypoxia-Inducible Factor 2-Alpha and Autophagy Mediates Drug Resistance in Colon Cancer Cells. Cancers (Basel). 2019 May 30;11(6). pii: E755. doi: 10.3390/cancers11060755.PMID:31151160

6.162

217. Pistillo MP, Carosio R, Banelli B, Morabito A, Mastracci L, Ferro P, Varesano S, Venè R, Poggi A, Roncella S. IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications

for the clinical response to PD-1/PD-L1 blockade. Cell Mol Immunol. 2020 Apr;17(4):410-411. doi: 10.1038/s41423-019-0245-x. Epub 2019 Jun 19. No abstract available.PMID:31217525
8.213

218. Benelli R, Barboro P, Costa D, Astigiano S, Barbieri O, Capaia M, Poggi A, Ferrari N. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer. Int J Mol Sci. 2019 Dec 3;20(23). pii: E6091. doi: 10.3390/ijms20236091.PMID:31816863
4.183

219. Di Mascolo D, Varesano S, Benelli R, Mollica H, Salis A, Zocchi MR, Decuzzi P, Poggi A. Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer. Cancers (Basel). 2019 Dec 31;12(1). pii: E104. doi: 10.3390/cancers12010104.PMID:31906080
6.162

220. Carrega P, Orecchia P, Quatrini L, Tumino N, Venè R, Benelli R, Poggi A, Scabini S, Mingari MC, Moretta L, Vacca P. Characterisation of innate lymphoid cell subsets infiltrating colorectal carcinoma. Gut. 2020 Mar 5. pii: gutjnl-2020-320908. doi: 10.1136/gutjnl-2020-320908. [Epub ahead of print] No abstract available.PMID:32139551
17.943

221 Venè R, Costa D, Augugliaro R, Carlone S, Scabini S, Casoni Pattacini G, Boggio M, Zupo S, Grillo F, Mastracci L, Pitto F, Minghelli S, Ferrari N, Tosetti F, Romairone E, Mingari MC, Poggi A, Benelli R. Evaluation of Glycosylated PTGS2 in Colorectal Cancer for NSAIDS-Based Adjuvant Therapy. Cells. 2020 Mar 11;9(3). pii: E683. doi: 10.3390/cells9030683. PMID:32168749.
5.656

222. Pistillo MP, Carosio R, Grillo F, Fontana V, Mastracci L, Morabito A, Banelli B, Tanda E, Cecchi F, Dozin B, Gualco M, Salvi S, Spagnolo F, Poggi A, Queirolo P. Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. Clin Immunol. 2020 Apr 25:108428. doi: 10.1016/j.clim.2020.108428. [Epub ahead of print]PMID:32344017
3.548

223. Benelli R, Costa D, Mastracci L, Grillo F, Olsen MJ, Barboro P, Poggi A, Ferrari N. Aspartate-β-Hydroxylase: A Promising Target to Limit the Local Invasiveness of Colorectal Cancer. Cancers (Basel). 2020 Apr 14;12(4). pii: E971. doi: 10.3390/cancers12040971.PMID:32295249.
6.162

224. Baci D, Bosi A,Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, and Mortara L.The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. *Int. J. Mol. Sci.* 2020, *21*(9), 3125; .
4.183

225. Mastracci L, Fontana V, Queirolo P, Carosio R, Grillo F, Morabito A, Banelli B, Tanda E, Boutros A, Dozin B, Gualco M, Salvi S, Romani M, Spagnolo F, Poggi A, Pistillo MP. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4^{+} tumor infiltrating lymphocytes and their in situ localization. Cancer Immunol Immunother. 2020 Apr;69(4):653-662. doi: 10.1007/s00262-020-02494-y. Epub 2020 Feb 5.
5.542.

226. Giuliani M, Poggi A**.** Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells. 2020 Jun 29;9(7):1578. doi: 10.3390/cells9071578.PMID: 32610578.
4.366.

227. Rossello A, Steinle A, Poggi A, Zocchi MR. Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor. Front Immunol. 2020 Jul 16;11:1483. doi: 10.3389/fimmu.2020.01483. eCollection 2020.PMID: 32765514.
5.085

228. Zocchi MR, Tosetti F, Benelli R, Poggi A. Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy. Cancers (Basel). 2020 Jul 13;12(7):E1886. doi: 10.3390/cancers12071886.PMID: 32668783.

6.126.

229. Barboro P, Benelli R, Tosetti F, Costa D, Capaia M, Astigiano S, Venè R, Poggi A, Ferrari N. Aspartate β-hydroxylase targeting in castration resistant prostate cancer modulates the NOTCH/ HIF1α/GSK3β crosstalk. Carcinogenesis. 2020 Jun 11:bgaa053. doi: 10.1093/carcin/bgaa053. Online ahead of print.PMID: 32525968.

4.004.

230 Tosetti F, Alessio M, Poggi A, Zocchi MR. ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease. Int J Mol Sci. 2021 May 7;22(9):4969. doi: 10.3390/ijms22094969. PMID: 34067041; PMCID: PMC8124674.

231. Poggi A, Zocchi MR. Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. Mol Ther Oncolytics. 2021 Nov 29;24:26-42. doi: 10.1016/j.omto.2021.11.016. PMID: 34977340; PMCID: PMC8693432.

232. Poggi A, Villa F, Fernadez JLC, Costa D, Zocchi MR, Benelli R. Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages. Cancers (Basel). 2021 Jul 8;13(14):3417. doi: 10.3390/cancers13143417. PMID: 34298630; PMCID: PMC8303518.

233. Poggi A. Co-signaling surface receptors: regulators of adaptive immune response. Comment on Shen H, *et al*. "Co-signaling receptors regulate T-cell plasticity and immune tolerance". Frontiers in Bioscience-Landmark. 2019; 24: 96-132. Front Biosci (Landmark Ed). 2021 Oct 30;26(10):675-677. doi: 10.52586/4977. PMID: 34719195.

234. Di Mascolo D, Varesano S, Benelli R, Mollica H, Salis A, Zocchi MR, Decuzzi P, Poggi A. Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer. Cancers (Basel). 2019 Dec 31;12(1):104. doi: 10.3390/cancers12010104. PMID: 31906080; PMCID: PMC7017311.

235. Carosio R, Fontana V, Mastracci L, Ferro P, Grillo F, Banelli B, Canessa PA, Dessanti P, Vigani A, Morabito A, Pfeffer U, Poggi A, Roncella S, Pistillo MP. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. J Cancer Res Clin Oncol. 2021 Feb;147(2):459-468. doi: 10.1007/s00432-020-03457-7. Epub 2020 Nov 20. PMID: 33216211.

236. Persano S, Vicini F, Poggi A, Fernandez JLC, Rizzo GMR, Gavilán H, Silvestri N, Pellegrino T. Elucidating the Innate Immunological Effects of Mild Magnetic Hyperthermia on U87 Human Glioblastoma Cells: An In Vitro Study. Pharmaceutics. 2021 Oct 12;13(10):1668. doi: 10.3390/pharmaceutics13101668. PMID: 34683961; PMCID: PMC8537446.

237. Alfano M, Locatelli I, D'Arrigo C, Mora M, Vozzi G, De Acutis A, Pece R, Tavella S, Costa D, Poggi A, Zocchi MR. Lysyl-Oxidase Dependent Extracellular Matrix Stiffness in Hodgkin Lymphomas: Mechanical and Topographical Evidence. Cancers (Basel). 2022 Jan 5;14(1):259. doi: 10.3390/cancers14010259. PMID: 35008423; PMCID: PMC8750937.

238. Benelli R, Zocchi MR, Poggi A. Evolution of 3D Cultures: Toward Tailored Preclinical Models. Cancers (Basel). 2023 Jan 14;15(2):515. doi: 10.3390/cancers15020515. PMID: 36672464; PMCID: PMC9857187.

239. Benelli R, Zocchi MR, Poggi A. Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer. Cancers (Basel). 2023 Feb 1;15(3):914. doi: 10.3390/cancers15030914. PMID: 36765872; PMCID: PMC9913607.

240. Hong J, Jin JO, Chen WY, Poggi A, Cheong JH. Editorial: Emerging roles and mechanisms of stromal cells in carcinomas at the molecular level. Front Immunol. 2022 Sep 8;13:1025838. doi: 10.3389/fimmu.2022.1025838. PMID: 36159814; PMCID: PMC9493345.

241. Poggi A. 10th Anniversary of Cells: Advances in Cellular Immunology-Regulation of Autoimmune Response and Antitumor Reactivity: Are They Two Side of the Same Coin? Cells. 2022 Dec 19;11(24):4122. doi: 10.3390/cells11244122. PMID: 36552886; PMCID: PMC9776996.

242. Merimi M, Fahmi H, De Kock J, Beguin C, Burny A, Moll G, Poggi A, Najar M. Mesenchymal Stem/Stromal Cells as a Therapeutic Tool in Cell-Based Therapy and Regenerative Medicine: An Introduction Expertise to the Topical Collection. Cells. 2022 Oct 8;11(19):3158. doi: 10.3390/cells11193158. PMID: 36231120; PMCID: PMC9562654.

243. Poggi A. Generation of Tumor Spheroids to Evaluate T Cell and NK Cell Cytotoxicity. Curr Protoc. 2022 Feb;2(2):e366. doi: 10.1002/cpz1.366. PMID: 35170872.

244. Pece R, Tavella S, Costa D, Varesano S, Camodeca C, Cuffaro D, Nuti E, Rossello A, Alfano M, D'Arrigo C, Galante D, Ravetti JL, Gobbi M, Tosetti F, Poggi A, Zocchi MR. Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect. Haematologica. 2022 Apr 1;107(4):909-920. doi: 10.3324/haematol.2021.278469. PMID: 34109776; PMCID: PMC8968898.

245. Marzagalli M, Pelizzoni G, Fedi A, Vitale C, Fontana F, Bruno S, Poggi A, Dondero A, Aiello M, Castriconi R, Bottino C, Scaglione S. A multi-organ-on-chip to recapitulate the infiltration and the cytotoxic activity of circulating NK cells in 3D matrix-based tumor model. Front Bioeng Biotechnol. 2022 Jul 25;10:945149. doi: 10.3389/fbioe.2022.945149. PMID: 35957642; PMCID: PMC9358021.

246. Matis S, Poggi A, Benelli R. microRNAs in Liquid Biopsy: The Way to a Simple and Rapid Test for Early Colorectal Cancer Diagnosis? Cancers (Basel). 2023 Jan 28;15(3):797. doi: 10.3390/cancers15030797. PMID: 36765755; PMCID: PMC9913811.

247. Poggi A, Matis S, Benelli R. The In Vitro Adaptation of Patient-Derived Organoids Suggests Alternative Strategies against CMS1 Colorectal Cancer: When the Microenvironment Does Make the Difference. Cancers (Basel). 2022 Dec 10;14(24):6086. doi: 10.3390/cancers14246086. PMID: 36551571; PMCID: PMC9775687.

248. Benelli R, Costa D, Salvini L, Tardito S, Tosetti F, Villa F, Zocchi MR, Poggi A. Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab. J Immunother Cancer. 2022 Dec;10(12):e005660. doi: 10.1136/jitc-2022-005660. PMID: 36543375; PMCID: PMC9772689.

249. Costa D, Venè R, Coco S, Longo L, Tosetti F, Scabini S, Mastracci L, Grillo F, Poggi A, Benelli R. SB202190 Predicts BRAF-Activating Mutations in Primary Colorectal Cancer Organoids via Erk1-2 Modulation. Cells. 2023 Feb 20;12(4):664. doi: 10.3390/cells12040664. PMID: 36831331; PMCID: PMC9954675.

250. Fernandez JLC, Benelli R, Costa D, Campioli A, Tavella S, Zocchi MR, Poggi A. Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes. Cancers (Basel). 2023 Jan 18;15(3):610. doi: 10.3390/cancers15030610. PMID: 36765569; PMCID: PMC9913507.

251. Tardito S, Matis S, Zocchi MR, Benelli R, Poggi A. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance. Int J Mol Sci. 2024 Jun 28;25(13):7131. doi: 10.3390/ijms25137131. PMID: 39000238; PMCID: PMC11241078.

252. Pisheh L, Matis S, Taglieri M, Di Gregorio L, Benelli R, Poggi A. EGFR-Targeted Antibody-Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells. Cancers (Basel). 2024 Mar 22;16(7):1256. doi: 10.3390/cancers16071256. PMID: 38610932; PMCID: PMC11011001.

253. Balkhi S, Bilato G, De Lerma Barbaro A, Orecchia P, Poggi A, Mortara L. Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies. Vaccines (Basel). 2025 Jan 13;13(1):69. doi: 10.3390/vaccines13010069. PMID: 39852848; PMCID: PMC11768832.

254. Tardito S, Matis S, Zocchi MR, Benelli R, Poggi A. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance. Int J Mol Sci. 2024 Jun 28;25(13):7131. doi: 10.3390/ijms25137131. PMID: 39000238; PMCID: PMC11241078.

255. Morelli F, Matis S, Benelli R, Salvini L, Zocchi MR, Poggi A. Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects. Cells. 2024 May 17;13(10):862. doi: 10.3390/cells13100862. PMID: 38786084; PMCID: PMC11119185.

256. Balkhi S, Di Spirito A, Poggi A, Mortara L. Immune Modulation in Alzheimer's Disease: From Pathogenesis to Immunotherapy. Cells. 2025 Feb 12;14(4):264. doi: 10.3390/cells14040264. PMID: 39996737; PMCID: PMC11853524.

257. Taglieri M, Di Gregorio L, Matis S, Uras CRM, Ardy M, Casati S, Marchese M, Poggi A, Raffaghello L, Benelli R. Colorectal Organoids: Models, Imaging, Omics, Therapy, Immunology, and Ethics. Cells. 2025 Mar 19;14(6):457. doi: 10.3390/cells14060457. PMID: 40136707; PMCID: PMC11941511.

Genoa, 23rd April 2025